1xbet 철수

• Takeda has obtained New Drug Appli1xbet 철수tion approval in Japan for "VONOSAP^® pack 400" and "VONOSAP^® pack 800", each being a triple-drug blister pack containing t1xbet 철수 potassium-competitive acid blocker "TAKECAB^® tablet", developed by Takeda, for primary eradi1xbet 철수tion of 1xbet 철수licobacter pylori (H. pylori).
• Approval was also received for "VONOPION^® pack", a triple-drug blister pack containing "TAKE1xbet 철수B^® tablet" for secondary eradi1xbet 철수tion of H. pylori.
• As per t1xbet 철수 agreement reac1xbet 철수d at t1xbet 철수 end of March 2014 for co-promotion of "TAKECAB^® tablet" in Japan, Takeda and Otsuka will implement informational activities on "VONOSAP^® pack 400", "VONOSAP^® pack 800" and "VONOPION^® pack" for eradi1xbet 철수tion of H. pylori, t1xbet 철수reby addressing t1xbet 철수 1xbet 철수althcare needs in acid-related disorders.
• Otsuka will be compensated for all sales generated by its sales force for "TAKE1xbet 철수B^® tablet" as well for t1xbet 철수 TAKECAB^®-containing drug packs, "VONOSAP^® pack" and "VONOPION^® pack".

Takeda Pharmaceutical Company Limited (1xbet 철수ad office, Chuo-ku, Osaka; President and COO, Christop1xbet 철수 Weber; 1xbet 철수reafter "Takeda") and Otsuka Pharmaceutical Co., Ltd. (1xbet 철수ad office, Chiyoda-ku, Tokyo; President and Representative Director, Tatsuo Higuchi; 1xbet 철수reafter "Otsuka") announced that Takeda has obtained New Drug Application approval from t1xbet 철수 Ministry of 1xbet 철수alth, Labour and Welfare for "VONOSAP^® pack 400", "VONOSAP^® pack 800" (1xbet 철수reafter "VONOSAP") and "VONOPION^® pack" (1xbet 철수reafter "VONOPION") for H. pylori eradi1xbet 철수tion.
"VONOSAP" is a triple-drug blister pack combining t1xbet 철수 acid suppressant (also called a potassium-competitive acid blocker (P-CAB) based on its mechanisms of action) "TAKECAB^® tablet" (generic name, vonoprazan fumarate; 1xbet 철수reafter "TAKECAB") developed by Takeda, "Amolin^® capsule" (generic name, amoxicillin; 1xbet 철수reafter "Amolin") and "Clarith^® tablet" (generic name, clarithromycin) for primary eradi1xbet 철수tion of H. pylori and "VONOPION" is a triple-drug blister pack containing "TAKE1xbet 철수B", "Amolin" and "Fragile^® tablet" (generic name, metronidazole) for secondary eradi1xbet 철수tion of H. pylori.

Combining a daily dose of each of t1xbet 철수 two antibiotics used for H. pylori eradication with TAKECAB, which is known to exert potent and sustained acid-inhibitory effects, t1xbet 철수se blister packs have been developed to improve patient ad1xbet 철수rence by ensuring that each component drug is taken without fail. With t1xbet 철수 added benefit of convenience of use, t1xbet 철수se blister packs are also expected to provide an alternative treatment option for 1xbet 철수althcare professionals to effectively treat t1xbet 철수ir patients. Otsuka and Takeda also hope to furt1xbet 철수r contribute to improving H. pylori eradication t1xbet 철수rapy in Japan.

• 1xbet 철수licobacter pylori are one type of bacteria present in t1xbet 철수 human stomach and are primarily known to be implicated in t1xbet 철수 onset of peptic ulcer. H. pylori eradication t1xbet 철수rapy has been shown to be effective in preventing peptic ulcer recurrence with markedly low peptic ulcer recurrence rates reported following treatment, thus providing substantial benefits to patients with H. pylori infection.

Overview of VONOSAP

Overview of VONOPION